Handelen Protagonist Therapeutics, Inc. - PTGX CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.08 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Protagonist Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 29.32 |
Open* | 29.12 |
1-Jaarlijkse Verandering* | 225.36% |
Dagelijks bereik* | 28.7 - 29.32 |
52 wekelijks bereik | 6.91-29.42 |
Weekgemiddelde volume (10 dagen) | 975.10K |
Gemiddeld volume (3 maanden) | 25.06M |
Marktkapitalisatie | 1.68B |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 57.25M |
Omzet | 859.00K |
EPS | -2.83 |
Dividend (opbrengst %) | N/A |
Beta | 1.96 |
Volgende inkomsten datum | Aug 2, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Jun 9, 2023 | 29.03 | -0.42 | -1.43% | 29.45 | 29.50 | 28.69 |
Jun 8, 2023 | 29.32 | 0.64 | 2.23% | 28.68 | 29.38 | 28.30 |
Jun 7, 2023 | 28.96 | 0.19 | 0.66% | 28.77 | 29.08 | 27.71 |
Jun 6, 2023 | 28.88 | 0.26 | 0.91% | 28.62 | 29.25 | 28.37 |
Jun 5, 2023 | 28.72 | 0.75 | 2.68% | 27.97 | 29.03 | 27.97 |
Jun 2, 2023 | 28.15 | 0.68 | 2.48% | 27.47 | 28.23 | 27.18 |
Jun 1, 2023 | 27.47 | 1.70 | 6.60% | 25.77 | 27.91 | 25.37 |
May 31, 2023 | 25.16 | -0.19 | -0.75% | 25.35 | 25.95 | 25.02 |
May 30, 2023 | 25.44 | -0.80 | -3.05% | 26.24 | 26.98 | 25.33 |
May 26, 2023 | 26.24 | 1.08 | 4.29% | 25.16 | 26.38 | 25.16 |
May 25, 2023 | 25.33 | -0.57 | -2.20% | 25.90 | 26.31 | 25.30 |
May 24, 2023 | 25.06 | 0.24 | 0.97% | 24.82 | 25.10 | 24.38 |
May 23, 2023 | 25.15 | -0.27 | -1.06% | 25.42 | 25.93 | 25.06 |
May 22, 2023 | 25.57 | -0.40 | -1.54% | 25.97 | 26.61 | 25.43 |
May 19, 2023 | 26.00 | 1.01 | 4.04% | 24.99 | 26.39 | 24.99 |
May 18, 2023 | 25.01 | -1.03 | -3.96% | 26.04 | 26.70 | 24.68 |
May 17, 2023 | 26.30 | 1.18 | 4.70% | 25.12 | 26.32 | 25.11 |
May 16, 2023 | 25.36 | 0.04 | 0.16% | 25.32 | 25.51 | 24.02 |
May 15, 2023 | 25.94 | 0.43 | 1.69% | 25.51 | 26.17 | 25.16 |
May 12, 2023 | 25.33 | 0.81 | 3.30% | 24.52 | 25.33 | 24.52 |
Protagonist Therapeutics, Inc. Events
Tijd (UTC) (UTC) | Land | Evenement |
---|---|---|
Wednesday, August 2, 2023 | ||
Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q2 2023 Protagonist Therapeutics Inc Earnings Release Q2 2023 Protagonist Therapeutics Inc Earnings ReleaseForecast -Previous - |
Monday, November 6, 2023 | ||
Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q3 2023 Protagonist Therapeutics Inc Earnings Release Q3 2023 Protagonist Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totale inkomsten | 26.581 | 27.357 | 28.628 | 0.231 | 30.925 |
Totale bedrijfskosten | 157.954 | 153.202 | 93.729 | 80.752 | 73.194 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 31.739 | 27.196 | 18.638 | 15.749 | 13.697 |
Onderzoek & Ontwikkeling | 126.215 | 126.006 | 74.506 | 65.003 | 59.497 |
Bedrijfsresultaat | -131.373 | -125.845 | -65.101 | -80.521 | -42.269 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 4.06 | 0.443 | 0.302 | 2.644 | 2.546 |
Overige, Netto | -0.08 | -0.149 | -0.046 | -0.001 | 0 |
Netto inkomen voor belastingen | -127.393 | -125.551 | -64.845 | -77.878 | -39.723 |
Netto inkomen na belastingen | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
Netto inkomen voor extra. Posten | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
Netto inkomen | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
Total Adjustments to Net Income | 0 | ||||
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
Verwaterd Netto Inkomen | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
Verwaterd Gewogen Gemiddelde Aandelen | 49.0422 | 46.3229 | 34.3965 | 25.894 | 22.3645 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -2.59762 | -2.71034 | -1.92316 | -2.98088 | -1.74044 |
Verwaterde Genormaliseerde Winst per Aandeel | -2.59762 | -2.71034 | -1.91211 | -2.98088 | -1.74044 |
Inkomsten | 26.581 | 27.357 | 28.628 | 0.231 | 30.925 |
Totale buitengewone posten | |||||
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Ongebruikelijke uitgaven (inkomsten) | 0 | 0 | 0.585 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totale inkomsten | 0 | 0 | 0 | 0.859 | 25.722 |
Inkomsten | 0 | 0 | 0 | 0.859 | 25.722 |
Totale bedrijfskosten | 36.021 | 36.516 | 32.303 | 42.302 | 46.833 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 8.605 | 6.632 | 6.901 | 7.691 | 10.515 |
Onderzoek & Ontwikkeling | 27.416 | 29.884 | 25.402 | 34.611 | 36.318 |
Bedrijfsresultaat | -36.021 | -36.516 | -32.303 | -41.443 | -21.111 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 2.491 | 2.251 | 1.157 | 0.484 | 0.168 |
Overige, Netto | -0.195 | 0.071 | -0.086 | -0.078 | 0.013 |
Netto inkomen voor belastingen | -33.725 | -34.194 | -31.232 | -41.037 | -20.93 |
Netto inkomen na belastingen | -33.725 | -34.194 | -31.232 | -41.037 | -20.93 |
Netto inkomen voor extra. Posten | -33.725 | -34.194 | -31.232 | -41.037 | -20.93 |
Netto inkomen | -33.725 | -34.194 | -31.232 | -41.037 | -20.93 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -33.725 | -34.194 | -31.232 | -41.037 | -20.93 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -33.725 | -34.194 | -31.232 | -41.037 | -20.93 |
Verwaterd Netto Inkomen | -33.725 | -34.194 | -31.232 | -41.037 | -20.93 |
Verwaterd Gewogen Gemiddelde Aandelen | 50.5737 | 49.2549 | 49.1076 | 49.0499 | 48.7525 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.66685 | -0.69422 | -0.63599 | -0.83664 | -0.42931 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Verwaterde Genormaliseerde Winst per Aandeel | -0.66685 | -0.69422 | -0.63599 | -0.83664 | -0.42931 |
Ongebruikelijke uitgaven (inkomsten) | 0 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totaal vlottende activa | 243.077 | 340.736 | 315.606 | 145.311 | 137.503 |
Geldmiddelen en kortetermijnbeleggingen | 237.355 | 326.9 | 305.809 | 133.017 | 128.853 |
Geldmiddelen & Equivalenten | 125.744 | 123.665 | 117.358 | 33.006 | 82.233 |
Korte Termijn Investeringen | 111.611 | 203.235 | 188.451 | 100.011 | 46.62 |
Totale Vorderingen, Netto | 0.052 | 5.333 | 3.821 | 7.499 | 6.511 |
Prepaid Expenses | 5.67 | 8.503 | 5.966 | 4.785 | 2.129 |
Other Current Assets, Total | 0.01 | 0.01 | 0.01 | ||
Total Assets | 247.928 | 347.695 | 324.468 | 154.917 | 139.472 |
Property/Plant/Equipment, Total - Net | 4.626 | 6.734 | 6.412 | 7.723 | 0.861 |
Property/Plant/Equipment, Total - Gross | 9.88 | 10.992 | 9.885 | 10.364 | 2.938 |
Accumulated Depreciation, Total | -5.254 | -4.258 | -3.473 | -2.641 | -2.077 |
Long Term Investments | 2 | ||||
Other Long Term Assets, Total | 0.225 | 0.225 | 0.45 | 1.883 | 1.108 |
Total Current Liabilities | 31.179 | 44.016 | 40.241 | 35.406 | 26.158 |
Accounts Payable | 3.64 | 1.6 | 3.075 | 2.79 | 5.711 |
Payable/Accrued | |||||
Accrued Expenses | 27.055 | 39.509 | 19.875 | 13.494 | 11.068 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 32.32 | 47.674 | 44.862 | 74.953 | 26.957 |
Total Long Term Debt | 0 | 0 | 0 | 9.794 | 0 |
Long Term Debt | 0 | 9.794 | |||
Total Equity | 215.608 | 300.021 | 279.606 | 79.964 | 112.515 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.00049 | 0.00048 | 0.00044 | 0.00027 | 0 |
Additional Paid-In Capital | 752.722 | 709.682 | 563.389 | 297.846 | 253.222 |
Retained Earnings (Accumulated Deficit) | -536.755 | -409.362 | -283.811 | -217.661 | -140.474 |
Other Equity, Total | -0.35949 | -0.29948 | 0.02756 | -0.22127 | -0.233 |
Total Liabilities & Shareholders’ Equity | 247.928 | 347.695 | 324.468 | 154.917 | 139.472 |
Total Common Shares Outstanding | 49.3392 | 47.8383 | 43.7455 | 27.2176 | 23.1872 |
Other Current Liabilities, Total | 0.484 | 2.907 | 17.291 | 19.122 | 9.379 |
Other Liabilities, Total | 1.141 | 3.658 | 4.621 | 29.753 | 0.799 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totaal vlottende activa | 235.736 | 243.077 | 276.617 | 304.302 | 341.522 |
Geldmiddelen en kortetermijnbeleggingen | 230.759 | 237.355 | 267.437 | 291.89 | 305.289 |
Geldmiddelen & Equivalenten | 127.686 | 125.744 | 152.816 | 120.237 | 98.477 |
Korte Termijn Investeringen | 103.073 | 111.611 | 114.621 | 171.653 | 206.812 |
Totale Vorderingen, Netto | 0.051 | 0.052 | 0.62 | 3.363 | 28.504 |
Prepaid Expenses | 4.926 | 5.67 | 8.56 | 9.049 | 7.729 |
Total Assets | 239.858 | 247.928 | 282.174 | 310.512 | 348.296 |
Property/Plant/Equipment, Total - Net | 3.897 | 4.626 | 5.332 | 5.985 | 6.549 |
Long Term Investments | |||||
Other Long Term Assets, Total | 0.225 | 0.225 | 0.225 | 0.225 | 0.225 |
Total Current Liabilities | 23.229 | 31.179 | 36.754 | 40.088 | 43.456 |
Accounts Payable | 4.021 | 3.64 | 4.715 | 1.412 | 7.159 |
Accrued Expenses | 18.852 | 27.055 | 31.816 | 38.336 | 34.995 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.356 | 0.484 | 0.223 | 0.34 | 1.302 |
Total Liabilities | 23.691 | 32.32 | 38.558 | 42.534 | 46.518 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.462 | 1.141 | 1.804 | 2.446 | 3.062 |
Total Equity | 216.167 | 215.608 | 243.616 | 267.978 | 301.778 |
Common Stock | 0.001 | 0.00049 | 0.00049 | 0.00049 | 0.00049 |
Additional Paid-In Capital | 786.768 | 752.722 | 746.657 | 740.027 | 732.542 |
Retained Earnings (Accumulated Deficit) | -570.48 | -536.755 | -502.561 | -471.329 | -430.292 |
Other Equity, Total | -0.122 | -0.35949 | -0.48049 | -0.72049 | -0.47249 |
Total Liabilities & Shareholders’ Equity | 239.858 | 247.928 | 282.174 | 310.512 | 348.296 |
Total Common Shares Outstanding | 51.4405 | 49.3392 | 49.1984 | 48.6839 | 48.5521 |
Other Current Assets, Total | |||||
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Property/Plant/Equipment, Total - Gross | 9.389 | 9.88 | 10.302 | 10.721 | 11.074 |
Accumulated Depreciation, Total | -5.492 | -5.254 | -4.97 | -4.736 | -4.525 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
Geldmiddelen uit Operationele Activiteiten | -108.137 | -107.865 | -72.484 | -41.527 | -49.947 |
Geldmiddelen uit Operationele Activiteiten | 1.034 | 0.813 | 0.789 | 0.703 | 0.527 |
Niet-Geldelijke Posten | 25.988 | 20.187 | 10.455 | 9.588 | 7.125 |
Veranderingen in het Operationeel Kapitaal | -7.766 | -3.314 | -19.016 | 26.144 | -18.017 |
Geldmiddelen uit Investeringsactiviteiten | 91.468 | -15.86 | -90.965 | -53.71 | 2.213 |
Kapitaaluitgaven | -0.795 | -1.101 | -0.471 | -0.967 | -0.486 |
Overige Cash Flow investeringsposten, Totaal | 92.263 | -14.759 | -90.494 | -52.743 | 2.699 |
Geldmiddelen uit Financieringsactiviteiten | 18.838 | 129.923 | 247.626 | 46.036 | 24.115 |
Uitgifte (Aflossing) van aandelen, netto | 19.001 | 130.112 | 258.164 | 36.271 | 24.115 |
Wisselkoerseffecten | -0.09 | -0.126 | 0.175 | -0.026 | -0.177 |
Nettowijziging in Geldmiddelen | 2.079 | 6.072 | 84.352 | -49.227 | -23.796 |
Deferred Taxes | 0 | 1.438 | -0.775 | -0.658 | |
Cash Taxes Paid | 0 | 0 | 0.438 | 0.07 | |
Uitgifte (Aflossing) van Schulden, Netto | 0 | -10.524 | 9.765 | ||
Financiering van Cash Flow Posten | -0.163 | -0.189 | -0.014 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -33.725 | -127.393 | -93.199 | -61.967 | -20.93 |
Cash From Operating Activities | -34.347 | -108.137 | -76.502 | -51.301 | -37.666 |
Cash From Operating Activities | 0.248 | 1.034 | 0.778 | 0.508 | 0.249 |
Non-Cash Items | 7.107 | 25.988 | 20.806 | 14.362 | 6.877 |
Changes in Working Capital | -7.977 | -7.766 | -4.887 | -4.204 | -23.862 |
Cash From Investing Activities | 9.826 | 91.468 | 87.533 | 30.258 | -4.476 |
Capital Expenditures | -0.01 | -0.795 | -0.725 | -0.563 | -0.273 |
Other Investing Cash Flow Items, Total | 9.836 | 92.263 | 88.258 | 30.821 | -4.203 |
Cash From Financing Activities | 26.463 | 18.838 | 18.285 | 17.605 | 16.925 |
Financing Cash Flow Items | -0.1 | -0.163 | -0.163 | -0.161 | -0.186 |
Issuance (Retirement) of Stock, Net | 26.563 | 19.001 | 18.448 | 17.766 | 17.111 |
Foreign Exchange Effects | 0 | -0.09 | -0.165 | 0.01 | 0.029 |
Net Change in Cash | 1.942 | 2.079 | 29.151 | -3.428 | -25.188 |
Deferred Taxes | 0 | ||||
Issuance (Retirement) of Debt, Net | 0 | ||||
Cash Taxes Paid | 0 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
RTW Investments L.P. | Investment Advisor/Hedge Fund | 8.0362 | 4600799 | 1008813 | 2023-03-31 | |
BVF Partners L.P. | Hedge Fund | 6.5953 | 3775900 | 3775900 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.7198 | 3274682 | 3008 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.6432 | 3230779 | 148535 | 2023-03-31 | LOW |
Adage Capital Management, L.P. | Hedge Fund | 5.1615 | 2955000 | 397000 | 2023-04-03 | MED |
Farallon Capital Management, L.L.C. | Hedge Fund | 4.5676 | 2615014 | -1036873 | 2023-03-31 | MED |
Johnson & Johnson Innovation-JJDC, Inc. | Venture Capital | 4.278 | 2449183 | 0 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.216 | 2413701 | -1379225 | 2023-03-31 | LOW |
Cormorant Asset Management, LP | Hedge Fund | 2.9694 | 1700000 | 1700000 | 2023-03-31 | LOW |
Kynam Capital Management LP | Hedge Fund | 2.4017 | 1375000 | 854078 | 2023-03-31 | HIGH |
Marshall Wace LLP | Investment Advisor/Hedge Fund | 2.3861 | 1366080 | -88366 | 2023-03-31 | HIGH |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 2.2048 | 1262259 | 185033 | 2023-03-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 2.0343 | 1164680 | -1190634 | 2023-03-31 | HIGH |
Millennium Management LLC | Hedge Fund | 1.9604 | 1122342 | -223047 | 2023-03-31 | HIGH |
Perceptive Advisors LLC | Private Equity | 1.6858 | 965152 | 965152 | 2023-03-31 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6174 | 925993 | 46102 | 2023-03-31 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 1.5127 | 866054 | 715931 | 2023-03-31 | LOW |
FundLogic SAS | Investment Advisor/Hedge Fund | 1.5075 | 863060 | -248227 | 2023-03-31 | HIGH |
Candriam Luxembourg S.A. | Investment Advisor | 1.5022 | 860000 | 235000 | 2023-04-30 | MED |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 1.4651 | 838806 | 838806 | 2023-03-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Protagonist Therapeutics, Inc. Company profile
Over Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is een biofarmaceutisch bedrijf in een klinische fase. Het bedrijf gebruikt zijn peptidentechnologieplatform om geneesmiddelen op basis van peptiden te ontdekken en te ontwikkelen om tegemoet te komen aan onbeantwoorde medische behoeften. Haar klinische programma's vallen onder twee categorieën van ziekten, waaronder hematologie en bloedstoornissen, en ontstekings- en immunomodulatoire ziekten. Haar belangrijkste klinische product, rusfertide (PTG-300), is een injecteerbaar hepcidinemeticum dat wordt ontwikkeld voor de behandeling van erytrocytose, ijzeroverbelasting en andere bloedziekten. Zijn andere klinische activa PTG-943 en PTG-200, zijn oraal toegediende onderzoeksgeneesmiddelen in ontwikkeling voor inflammatoire darmziekten (IBD) die zijn ontworpen om biologische routes te blokkeren waarop wordt gemikt door op de markt gebrachte injecteerbare antilichaamgeneesmiddelen. De PN-235 en PN-232, IL-R-antagonisten, zijn in klinische ontwikkeling. Protagonist Pty Limited is zijn dochteronderneming.
Industry: | Biotechnology & Medical Research (NEC) |
7707 Gateway Blvd Ste 140
NEWARK
CALIFORNIA 94560-1160
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen